LOUISVILLE, Ky. — Treatment with add-on dupilumab (Dupixent) was linked with clinically meaningful improvements in hives and itch severity in patients with chronic spontaneous urticaria (CSU), according to the LIBERTY-CSU CUPID Study A trial.
In patients as young as 6 years with itch and hives that were not adequately controlled on antihistamine treatment alone, dupilumab plus H1 antihistamines significantly reduced itch, hives, and urticaria activity in the phase III, 24-week trial in both patients with low baseline serum total IgE (